Weight of evidence in safety pharmacology guidance: A case for explicit probabilistic reasoning in the revision of ICH S7A.

ICH S7A (2000) defined the foundational framework for safety pharmacology studies supporting the registration of human pharmaceuticals. Overall, the guidance applied a risk-based, rational scope combined with a prescriptive framework of core battery endpoints collected under GLP guidelines that were required prior to first-in-human testing. Because of the evolving landscape of pharmaceutical modalities, nonclinical methodologies, and regulatory science over the last two decades, a critical examination of its relationship to weight-of-evidence (WoE) and risk-based reasoning is warranted. The central challenge is not that S7A lacks scientific flexibility in principle, but that its operational default has become a checklist that is often easier to execute, review and defend than an explicitly reasoned alternative. In the absence of an explicit WoE or probabilistic framework, sponsors and regulators are drawn toward the established paradigm of completing the S7A core battery, which renders the guideline's broader flexibility more aspirational than operational. The persistence of this 'default' is structurally understandable; sponsors, contract research organizations, and regulators each have legitimate institutional reasons to prefer a defined expectation over open-ended case-by-case judgment. A revision that simply endorses WoE in principle, without providing operational architecture for its application, is therefore unlikely to change practice and improve nonclinical safety assessment. This manuscript examines the structural tension within S7A, identifies the implicit WoE provisions already present in the guidance, analyzes the institutional forces that sustain prescriptive implementations, and proposes a practical resolution in which integrated evidence is used to select among a limited number of predefined assessment strategies, illustrated here with worked examples spanning contemporary modalities. In this way, the manuscript argues not for a departure from the original intent of the ICH S7A guidance but rather a reframing of the content to reflect contemporary drug development needs while accommodating the future modality landscape.